Cargando…

Patients’ Perspectives on Commencing Oral Anticoagulants in Atrial Fibrillation: An Exploratory Qualitative Descriptive Study

Background: Oral anticoagulants (OACs) are prescribed to patients with atrial fibrillation (AF) in order to lower stroke risk. However, patient refusal to commence OACs hinders effective anticoagulation. This study aimed to explore barriers and facilitators to patient agreement to commence OACs from...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebreyohannes, Eyob Alemayehu, Salter, Sandra M., Chalmers, Leanne, Radford, Jan, Lee, Kenneth, D’Lima, Danielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609834/
https://www.ncbi.nlm.nih.gov/pubmed/37888498
http://dx.doi.org/10.3390/pharmacy11050153
_version_ 1785128107998445568
author Gebreyohannes, Eyob Alemayehu
Salter, Sandra M.
Chalmers, Leanne
Radford, Jan
Lee, Kenneth
D’Lima, Danielle
author_facet Gebreyohannes, Eyob Alemayehu
Salter, Sandra M.
Chalmers, Leanne
Radford, Jan
Lee, Kenneth
D’Lima, Danielle
author_sort Gebreyohannes, Eyob Alemayehu
collection PubMed
description Background: Oral anticoagulants (OACs) are prescribed to patients with atrial fibrillation (AF) in order to lower stroke risk. However, patient refusal to commence OACs hinders effective anticoagulation. This study aimed to explore barriers and facilitators to patient agreement to commence OACs from the perspectives of patients with AF attending Australian general practices. Methods: A qualitative descriptive study utilising semi-structured individual interviews was conducted from March to July 2022. Results: Ten patients (60% male, median age = 78.5 years) completed interviews. Patients’ passive roles in decision-making were identified as a facilitator. Other prominent facilitators included doctors explaining adequately and aligning their recommendations with patients’ overall health goals, including the prevention of stroke and associated disabilities, and a clear understanding of the pros and cons of taking OACs. Reportedly insufficient explanation from doctors and the inconvenience associated with taking warfarin were identified as potential barriers. Conclusion: Addressing factors that influence patient agreement to commence OACs should be an essential aspect of quality improvement interventions. Subsequent studies should also delve into the perspectives of eligible patients with AF who choose not to commence OACs as well as the perspectives of both patients and doctors regarding the decision to continue OAC treatment.
format Online
Article
Text
id pubmed-10609834
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106098342023-10-28 Patients’ Perspectives on Commencing Oral Anticoagulants in Atrial Fibrillation: An Exploratory Qualitative Descriptive Study Gebreyohannes, Eyob Alemayehu Salter, Sandra M. Chalmers, Leanne Radford, Jan Lee, Kenneth D’Lima, Danielle Pharmacy (Basel) Article Background: Oral anticoagulants (OACs) are prescribed to patients with atrial fibrillation (AF) in order to lower stroke risk. However, patient refusal to commence OACs hinders effective anticoagulation. This study aimed to explore barriers and facilitators to patient agreement to commence OACs from the perspectives of patients with AF attending Australian general practices. Methods: A qualitative descriptive study utilising semi-structured individual interviews was conducted from March to July 2022. Results: Ten patients (60% male, median age = 78.5 years) completed interviews. Patients’ passive roles in decision-making were identified as a facilitator. Other prominent facilitators included doctors explaining adequately and aligning their recommendations with patients’ overall health goals, including the prevention of stroke and associated disabilities, and a clear understanding of the pros and cons of taking OACs. Reportedly insufficient explanation from doctors and the inconvenience associated with taking warfarin were identified as potential barriers. Conclusion: Addressing factors that influence patient agreement to commence OACs should be an essential aspect of quality improvement interventions. Subsequent studies should also delve into the perspectives of eligible patients with AF who choose not to commence OACs as well as the perspectives of both patients and doctors regarding the decision to continue OAC treatment. MDPI 2023-09-23 /pmc/articles/PMC10609834/ /pubmed/37888498 http://dx.doi.org/10.3390/pharmacy11050153 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gebreyohannes, Eyob Alemayehu
Salter, Sandra M.
Chalmers, Leanne
Radford, Jan
Lee, Kenneth
D’Lima, Danielle
Patients’ Perspectives on Commencing Oral Anticoagulants in Atrial Fibrillation: An Exploratory Qualitative Descriptive Study
title Patients’ Perspectives on Commencing Oral Anticoagulants in Atrial Fibrillation: An Exploratory Qualitative Descriptive Study
title_full Patients’ Perspectives on Commencing Oral Anticoagulants in Atrial Fibrillation: An Exploratory Qualitative Descriptive Study
title_fullStr Patients’ Perspectives on Commencing Oral Anticoagulants in Atrial Fibrillation: An Exploratory Qualitative Descriptive Study
title_full_unstemmed Patients’ Perspectives on Commencing Oral Anticoagulants in Atrial Fibrillation: An Exploratory Qualitative Descriptive Study
title_short Patients’ Perspectives on Commencing Oral Anticoagulants in Atrial Fibrillation: An Exploratory Qualitative Descriptive Study
title_sort patients’ perspectives on commencing oral anticoagulants in atrial fibrillation: an exploratory qualitative descriptive study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609834/
https://www.ncbi.nlm.nih.gov/pubmed/37888498
http://dx.doi.org/10.3390/pharmacy11050153
work_keys_str_mv AT gebreyohanneseyobalemayehu patientsperspectivesoncommencingoralanticoagulantsinatrialfibrillationanexploratoryqualitativedescriptivestudy
AT saltersandram patientsperspectivesoncommencingoralanticoagulantsinatrialfibrillationanexploratoryqualitativedescriptivestudy
AT chalmersleanne patientsperspectivesoncommencingoralanticoagulantsinatrialfibrillationanexploratoryqualitativedescriptivestudy
AT radfordjan patientsperspectivesoncommencingoralanticoagulantsinatrialfibrillationanexploratoryqualitativedescriptivestudy
AT leekenneth patientsperspectivesoncommencingoralanticoagulantsinatrialfibrillationanexploratoryqualitativedescriptivestudy
AT dlimadanielle patientsperspectivesoncommencingoralanticoagulantsinatrialfibrillationanexploratoryqualitativedescriptivestudy